2024
Clinical outcomes and immunological response to SARS-CoV-2 infection among people living with HIV
Amegashie E, Asamoah P, Ativi L, Adusei-Poku M, Bonney E, Tagoe E, Paintsil E, Torpey K, Quaye O. Clinical outcomes and immunological response to SARS-CoV-2 infection among people living with HIV. Experimental Biology And Medicine 2024, 249: 10059. PMID: 38628843, PMCID: PMC11020089, DOI: 10.3389/ebm.2024.10059.Peer-Reviewed Original ResearchConceptsLevels of inflammatory markersResponse to SARS-CoV-2 infectionClinical outcomesSARS-CoV-2 infectionCo-infectionInflammatory markersSARS-CoV-2HIV patients co-infectedImmune response to SARS-CoV-2 infectionCD4<sup>+</sup> countInitiation of ARTT cell exhaustionPatients co-infectedSevere outcomesAssociated with severe outcomesStudy assessed risk factorsMono-infected individualsResponse to SARS-CoV-2Respiratory tract infectionsImmunological response to SARS-CoV-2Immunological response to SARS-CoV-2 infectionAfrican American raceChronic kidney diseaseIntensive care unitPositive conversion rate
2023
Pediatric HIV Disclosure Intervention Improves Immunologic Outcome at 48 Weeks: The Sankofa Trial Experience
Shabanova V, Emuren L, Gan G, Antwi S, Renner L, Amissah K, Kusah J, Lartey M, Reynolds N, Paintsil E. Pediatric HIV Disclosure Intervention Improves Immunologic Outcome at 48 Weeks: The Sankofa Trial Experience. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2023, 94: 371-380. PMID: 37643414, PMCID: PMC10617661, DOI: 10.1097/qai.0000000000003292.Peer-Reviewed Original ResearchConceptsHIV disclosure interventionsVirologic outcomesCD4 percentWeek 48HIV statusIntervention groupHIV disclosureDisclosure interventionDetectable viral loadWorld Health OrganizationAntiretroviral therapyImmunologic outcomesClinical outcomesIntervention armViral loadControl armClinical trialsTrial experienceSecondary analysisDisclosure statusHealth OrganizationCategorical variablesWeeksLinear mixed modelsBaseline